Hematopoiesis & Hematologic Malignancies

$75,139P30FY2025CANIH

Indiana University Indianapolis, Indianapolis IN

Investigators

Linked publications, trials & patents

Paper 39635662 Paper 39562169 Paper 39558163 Paper 39401251 Paper 39345446 Paper 39345410 Paper 39318189 Paper 39271111 Paper 39210605 Paper 39120644 Paper 39088391 Paper 39087253 Paper 39078738 Paper 39058312 Paper 39039946 Paper 39009814 Paper 39002124 Paper 38958700 Paper 38923150 Paper 38916922 Paper 38915654 Paper 38904214 Paper 38893159 Paper 38887549 Paper 38798459 Paper 38787155 Paper 38755140 Paper 38747593 Paper 38699339 Paper 38687615 Paper 38682338 Paper 38630048 Paper 38559125 Paper 38537322 Paper 38493956 Paper 38440160 Paper 38429294 Paper 38398074 Paper 38364811 Paper 38311014 Paper 38274806 Paper 38269754 Paper 38266162 Paper 38254905 Paper 38205644 Paper 38127282 Paper 38117580 Paper 38105991 Paper 38105923 Paper 38062757 Paper 38059556 Paper 38056311 Paper 38055903 Paper 38053332 Paper 38042447 Paper 38023622 Paper 38023147 Paper 38019093 Paper 38014106 Paper 37998322 Paper 37971174 Paper 37954612 Paper 37938185 Paper 37913777 Paper 37890164 Paper 37884051 Paper 37877735 Paper 37832101 Paper 37819759 Paper 37798249 Paper 37793345 Paper 37741264 Paper 37699885 Paper 37645961 Paper 37645016 Paper 37621654 Paper 37600810 Paper 37577665 Paper 37562535 Paper 37546395 Paper 37491208 Paper 37479733 Paper 37462073 Paper 37444419 Paper 37406085 Paper 37398039 Paper 37350478 Paper 37280534 Paper 37280243 Paper 37192286 Paper 37172907 Paper 37142441 Paper 37137681 Paper 37057595 Paper 37038957 Paper 37014943 Paper 36943734 Paper 36943285 Trial NCT02020941 Trial NCT00898378

Abstract

The HHM Research Program is a basic science research program built on robust transdisciplinary collaborations to catalyze impactful research and team science. The Program is devoted to mentoring new faculty to become experts in the field, nourishing our team members, and supporting IUSCCC efforts in the community. In the current grant period, we had two themes. Theme 1, Hematopoiesis, aimed to understand the mechanistic regulation of hematopoietic stem cells (HSCs) and progenitor cells (HPCs), enhance mobilization of HSCs and HPCs for better transplant engraftment, and identify novel biomarkers and therapeutic targets to modulate Graft vs. Host Disease. Theme 2, Hematological Malignancies, aimed to clarify the cellular processes and intracellular signaling that drive the biology of hematologic malignancies and to better understand the relationship between hematologic malignancies and the bone microenvironment. Significant advances were made over that period. As part of HHM strategic planning (with input from the IUSCCC Director, Executive Committee, and EAB) to support the IUSCCC mission to lift the burden of cancer in Indiana and with additional recently recruited translational scientists, we plan to transition the HHM Program from a basic science to a translational research program over the next grant period. Our long-term goal is to advance treatment of hematologic malignancies through rigorous discoveries that will lead to novel biomarkers and therapeutics. Our overall themes remain the same, providing a comprehensive and complementary paradigm to address initiation, progression, and targeting of hematological cancers within their hostile niche and the pathway to successful therapy development.

View original record on NIH RePORTER →